Vice President, Early Clinical Development, Radiopharmaceutical Therapies

Career Areas Career Stories Join Talent Community Candidate Login English English Italiano Español Français Português Norsk Deutsch 日本語 Bahasa melayu 中文 (简体) 中文 (繁體) 한국어 ภาษาไทย Nederlands Polski Yкраїнська Hrvatski Ελληνικά Magyar čeština Türkçe Pусский Haitian עברית Brazilian Português Dansk Suomi Svenska Français (Canada) Português (Portugal) Careers Home Life at BMS Career Areas Student Opportunities Events How We Recruit Career Stories Search this site Join Talent Community Candidate Login English English Italiano Español Français Português Norsk Deutsch 日本語 Bahasa melayu 中文 (简体) 中文 (繁體) 한국어 ภาษาไทย Nederlands Polski Yкраїнська Hrvatski Ελληνικά Magyar čeština Türkçe Pусский Haitian עברית Brazilian Português Dansk Suomi Svenska Français (Canada) Português (Portugal) Single PositionView All JobsRemoteVice President, Early Clinical Development, Radiopharmaceutical TherapiesRemote - United States - US No longer accepting applications.Job IDR1604365Date posted07/09/2026DepartmentOncologyRayzeBio, a Bristol Myers Squibb company, is a dynamic biotechnology company headquartered in San Diego, CA. The company is focused on improving survival of people with cancer by harnessing the power of targeted radioisotopes. RayzeBio is developing innovative drugs against targets of solid tumors. Led by a successful and experienced entrepreneurial team, RayzeBio aims to be the global leader in radiopharmaceuticals. Position SummaryThis role will report to the CMO and hold a key leadership position within the clinical development organization and will serve as the bridge between research, discovery, and clinical development. The Vice President of Early Development will lead the clinical strategy and medical oversight for the RayzeBio portfolio of next-generation radiopharmaceutical therapies. This role is responsible for the "First-in-Human" journey, transforming preclinical discoveries into robust, data-driven clinical programs that demonstrate early safety, biological activity, and therapeutic potential. This role provides medical direction and high quality scientific and clinical knowledge to lead the strategy and execution of RayzeBio’s clinical development plans for molecules in early development. Responsibilities include support for IND preparation, regulatory authority interactions, design and execution of Phase 0/1 FIH clinical trials. This role will lead cross-functional teams responsible for the design, implementation, monitoring, analysis, and reporting of studies conducted within RayzeBio’s portfolio to ensure the program meets the needs of patients and RayzeBio’s business. This role will engage with BMS oncology leaders in research and early clinical development to develop combination strategies as appropriate across the BMS and Rayze Bio portfolios.Key Responsibilities Clinical Development Strategy: Design and execute innovative Phase 0/1 clinical trials. Define the clinical path to proof-of-concept, including the use of theranostic pairs to accelerate patient selection.Translational & Medical Oversight: Lead the translation of preclinical pharmacology and toxicology into First-in-Human dosing strategies. Serve as the primary medical/scientific voice for the early-stage pipeline.Dosimetry & PK/PD: Collaborate with medical physicists to integrate radiation dosimetry into clinical protocols, ensuring optimized therapeutic windows and individualized patient safety.Imaging Strategy: Define the imaging strategy to provide early evidence of target engagement, biodistribution, and tumor response.Regulatory Liaison: Act as the lead clinical expert for meetings with global health authorities (FDA/EMA). Draft and defend clinical sections of IND/CTA filings, with a focus on justifying dose-escalation schemes and safety monitoring. Support and lead interactions with the FDA’s Division of Medical Imaging and Radiation Medicine.KOL Collaboration: Establish a network of academic investigators and nuclear medicine specialists to ensure...